Brief: Protagonist Therapeutics Q1 EPS USD 0.05
05/05/2026 21:05
May 05 (Reuters) - Protagonist Therapeutics Q1 license and collaboration revenue USD 56.368 million. Q1 operating expenses USD 60.016 million Q1 net income USD 3.783 million Q1 income from operations USD -3.648 million
Recent news on Protagonist Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Adobe, Braveheart Bio, CACI International
US FDA approves Takeda, Protagonist's drug for rare blood cancer (updated)
US FDA approves Takeda, Protagonist's drug for rare blood cancer
Silence Therapeutics jumps after mid-stage trial data for blood cancer drug
Protagonist Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary